Budoprutug's early ITP platelet responses and pMN Fast Track set the stage, but Phase 2 registrational data will determine if B-cell depletion translates to durable clinical benefit

Bull

A positive outcome would show that the 1000 mg dose achieves near-complete B-cell depletion with durable platelet responses (sustained counts ≥100×10³/µL) in a meaningful proportion of patients, including those refractory to prior rituximab. This would validate the dose-response relationship, de-risk the path to a registrational Phase 2, and establish budoprutug as a best-in-class anti-CD19 B-cell depleter in ITP with a differentiated profile over rituximab.

Bear

The primary failure mode would be a lack of incremental benefit at the higher 1000 mg dose relative to the 250 mg cohort, suggesting a plateau in B-cell depletion or platelet response that limits differentiation from existing therapies. Alternatively, safety signals — such as serious infections or Grade 3+ adverse events — emerging at higher doses could constrain dose escalation and undermine the registrational path, while shallow or non-durable platelet responses in a broader patient population would call into question whether B-cell depletion alone is sufficient to drive clinical benefit in ITP.